Response to Potestio et al., “Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review” - 19/05/25
Doi : 10.1016/j.jaad.2024.11.083
Siddhartha Sood, HBSc a, Alexander Rimke, MSc b, Brian D. Rankin, MD, PhD c, Abrahim Abduelmula, MD d, Jorge R. Georgakopoulos, MD d, Khalad Maliyar, MD d, Ahmed Bagit, BSc a, Fernejoy Leung e, Alim R. Devani, MD b, e, h, Ronald Vender, MD f, g, Jensen Yeung, MD d, h, i, j, Vimal H. Prajapati, MD, FRCPC b, c, e, k, l, m, ⁎ 
a Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
b Dermatology Research Institute, Calgary, Alberta, Canada
c Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
d Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
e Skin Health & Wellness Centre, Calgary, Alberta, Canada
f Division of Dermatology, McMaster University, Hamilton, Ontario, Canada
g Dermatrials Research Inc. & Venderm Consulting, Hamilton, Ontario, Canada
h Probity Medical Research, Waterloo, Ontario, Canada
i Division of Dermatology, Department of Medicine, Women’s College Hospital, Toronto, Ontario, Canada
j Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
k Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
l Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
m Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
∗Correspondence to: Vimal H. Prajapati, MD, Dermatology Research Institute, Suite 310, 8500 Blackfoot Trail S.E., Calgary, Alberta, Canada | T2J 7E1Dermatology Research InstituteSuite 3108500 Blackfoot Trail S.E.CalgaryAlbertaT2J 7E1Canada
Key words : bimekizumab, biologic, biologic switch, intra-class, psoriasis, real-world experience
Le texte complet de cet article est disponible en PDF.
| Drs Prajapati and Yeung contributed equally to this article as co-senior authors. |
|
| Funding sources: None. |
|
| IRB approval status: IRB approval was obtained by the research ethics boards at each respective academic institution from which data were collected (Sunnybrook Health Sciences Centre [205-2018]; Women’s College Hospital [2018-0079-E]). |
|
| Patient consent: Requirements for patient consent were waived for this study due to the use of anonymized and deidentified data. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 92 - N° 6
P. e191-e193 - juin 2025 Retour au numéro
Article précédent
- Response to Sood et al’s “Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review”
- Luca Potestio, Fabrizio Martora, Matteo Megna
- Response to Folliat et al’s “Characteristics of pruritus in lichen planopilaris and frontal fibrosing alopecia: A cohort study in a French hospital”
- Jeremiah S. Truel, Madison Novice, Jerry Shapiro, Kristen I. Lo Sicco
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?